Connection
Craig Jordan to Cyclin-Dependent Kinase Inhibitor p16
This is a "connection" page, showing publications Craig Jordan has written about Cyclin-Dependent Kinase Inhibitor p16.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.366 |
|
|
|
-
Wang PY, Young F, Chen CY, Stevens BM, Neering SJ, Rossi RM, Bushnell T, Kuzin I, Heinrich D, Bottaro A, Jordan CT. The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. Blood. 2008 Nov 15; 112(10):4184-92.
Score: 0.294
-
Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. Biol Blood Marrow Transplant. 2008 Jun; 14(6):622-30.
Score: 0.072